Memphasys Limited (ASX:MEM)

Market Cap	9.92M
Revenue (ttm)	1.07M
Net Income (ttm)	-5.11M
Shares Out	1.98B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,975,112
Average Volume	5,490,986
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0040 - 0.0120
Beta	0.84
RSI	31.07
Earnings Date	May 29, 2025

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 24
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MEM

Financial Performance

In 2024, Memphasys's revenue was 1.09 million, an increase of 74.55% compared to the previous year's 624,370. Losses were -4.44 million, 30.5% more than in 2023.